Genetic Determinants of P2Y12 Inhibitors and Clinical Implications

Larisa H. Cavallari, Aniwaa Owusu Obeng

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


There is significant interpatient variability in clopidogrel effectiveness, which is due in part to cytochrome P450 (CYP) 2C19 genotype. Approximately 30% of individuals carry CYP2C19 loss-of-function alleles, which have been consistently shown to reduce clopidogrel effectiveness after an acute coronary syndrome and percutaneous coronary intervention. Guidelines recommend consideration of prasugrel or ticagrelor in these patients. A clinical trial examining outcomes with CYP2C19 genotype–guided antiplatelet therapy is ongoing. In the meantime, based on the evidence available to date, several institutions have started clinically implementing CYP2C19 genotyping to assist with antiplatelet selection after percutaneous coronary intervention.

Original languageEnglish
Pages (from-to)141-149
Number of pages9
JournalInterventional Cardiology Clinics
Issue number1
StatePublished - 1 Jan 2017


  • CYP2C19
  • Clopidogrel
  • Genotype
  • Pharmacogenomics
  • Prasugrel
  • Ticagrelor


Dive into the research topics of 'Genetic Determinants of P2Y12 Inhibitors and Clinical Implications'. Together they form a unique fingerprint.

Cite this